skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants

Heliyon, 2024-03, Vol.10 (5), p.e27033-e27033, Article e27033 [Peer Reviewed Journal]

2024 The Authors ;2024 The Authors. ;2024 The Authors 2024 ;ISSN: 2405-8440 ;EISSN: 2405-8440 ;DOI: 10.1016/j.heliyon.2024.e27033 ;PMID: 38486776

Full text available

Citations Cited by
  • Title:
    Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants
  • Author: Planas, Delphine ; Peng, Lin ; Zheng, Lingyi ; Guivel-Benhassine, Florence ; Staropoli, Isabelle ; Porrot, Françoise ; Bruel, Timothée ; Bhiman, Jinal N. ; Bonaparte, Matthew ; Savarino, Stephen ; de Bruyn, Guy ; Chicz, Roman M. ; Moore, Penny L. ; Schwartz, Olivier ; Sridhar, Saranya
  • Subjects: Booster ; COVID-19 ; Neutralizing antibody ; Randomized controlled trial ; SARS CoV-2 ; Vaccines
  • Is Part Of: Heliyon, 2024-03, Vol.10 (5), p.e27033-e27033, Article e27033
  • Description: SARS-CoV-2 Omicron lineage contains variants with multiple sequence mutations relative to the ancestral strain particularly in the viral spike gene. These mutations are associated inter alia with loss of neutralization sensitivity to sera generated by immunization with vaccines targeting ancestral strains or prior infection with circulating (non-Omicron) variants. Here we present a comparison of vaccine formulation elicited cross neutralization responses using two different assay readouts from a subpopulation of a Phase II/III clinical trial. Human sera from a Phase II/III trial (NCT04762680) was collected and evaluated for neutralizing responses to SARS-CoV-2 spike antigen protein vaccines formulated with AS03 adjuvant, following a primary series of two-doses of ancestral strain vaccine in individuals who were previously unvaccinated or as an ancestral or variant strain booster vaccine among individuals previously vaccinated with the mRNA BNT162b2 vaccine. We report that a neutralizing response to Omicron BA.1 is induced by the two-dose primary series in 89% of SARS-CoV-2-seronegative individuals. A booster dose of each vaccine formulation raises neutralizing antibody titers that effectively neutralizes Omicron BA.1 and BA.4/5 variants. Responses are highest after the monovalent Beta variant booster and similar in magnitude to human convalescent plasma titers. The findings of this study suggest the possibility to generate greater breadth of cross-neutralization to more recently emerging viral variants through use of a diverged spike vaccine in the form of a Beta variant booster vaccine.
  • Publisher: England: Elsevier Ltd
  • Language: English
  • Identifier: ISSN: 2405-8440
    EISSN: 2405-8440
    DOI: 10.1016/j.heliyon.2024.e27033
    PMID: 38486776
  • Source: DOAJ Directory of Open Access Journals
    PubMed Central
    ROAD: Directory of Open Access Scholarly Resources
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait